Instruction for use: Estradiol valerate (Oestradioli valeras)

Pharmacological group of substance Estradiol

Estrogens, gestagens; their homologues and antagonists

Nosological classification (ICD-10)

E28.3 Primary ovarian failure

Hypogonadism of the ovary (primary), Hypofunction of the ovaries, Estrogen deficiency, Insufficient estrogen content in the body, Insufficiency estrogenic, Insufficiency of estrogens, Primary dysfunction of the ovaries, Estrogen-deficient conditions

E28.8 Other types of ovarian dysfunction

L98.9 Lesion of skin and subcutaneous tissue, unspecified

Adiponecrosis, Atonic leather, Diseases of the skin, Blister, Inflammatory disease of soft tissues, Inflammatory processes of epithelial tissues, Degenerative changes in the skin and mucous membranes, Degenerative changes in the skin and mucous membranes, Excess granulation, Thinning of the skin, Skin diseases, Maceration of the skin, Minor skin lesions, Surface crack and skin abrasion, Increased skin peeling, Skin lesion, Erosion of the skin, Lipedema, Local non-infectious processes of skin and soft tissues, Disturbance of skin structure, Dysfunction of the skin, Skin disorders

M81.0 Postmenopausal osteoporosis

Menopause osteoporosis, Osteoporosis in menopause, Osteoporosis in menopause, Osteoporosis in postmenopausal women, Osteoporosis in the postmenopausal period, Postmenopausal osteoporosis, Osteoporosis in postmenopausal women, Perimenopausal osteoporosis, Postmenopausal osteoporosis, Post-menopausal osteoporosis, Postmenopausal osteoporosis, Postmenopausal demineralization of bones, Osteoporosis with estrogen deficiency, Osteoporosis in postmenopausal women, Osteoporosis in postmenopausal women and after hysterectomy

N32.9 Disorders of bladder, unspecified

Atrophy of the sphincter of the bladder

N95.1 menopausal and menopausal status of women

Atrophy of the mucosa of the lower genital tract, caused by estrogen deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoestrogeniya state; Deficiency of estrogen in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of estrogen; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Estrogendefitsitnye state; premature Menopause

Code CAS 979-32-8

Pharmacology

The pharmacological action is estrogenic.

Replenishes the inadequate production of endogenous estrogens. Regulates the exchange of fats, proteins and carbohydrates, water-electrolyte balance, lowers the level of LDL cholesterol in the blood; causes proliferative changes in the endometrium, prevents the reduction of bone mass and osteoporosis. It relieves somatic, mental and other climacteric symptoms during pre- and postmenopausal periods or after ovariectomy.

Application of Estradiol valerate

Estrogen insufficiency (menopause, postmenopausal period, ovariectomy for benign diseases, radiation castration), associated with vasomotor symptoms (hot flashes, headache), sleep disorders, depressive states, irritability, nervousness, increased sweating, dizziness; bladder hypoesthesia; degenerative changes in the skin and mucous membranes; prevention of osteoporosis in the climacteric period.

Contraindications

Hypersensitivity, endometrial hyperplasia, endometriosis, myoma, breast cancer or suspected of it, other hormone-dependent neoplasms or suspicion of them, benign or malignant liver tumors (including in the anamnesis), severe violations of the liver function, thromboembolic processes (in tons in history), diabetes mellitus, congenital disorders of fat metabolism, hypertriglyceridemia, Dubin-Johnson and Rotor syndromes, vaginal bleeding of unknown origin, otosclerosis with exacerbation during the previous pregnancy and, pregnancy, breast-feeding.

Side effects of Estradiol valerate

Headache, nausea, uterine bleeding, exacerbation of endometriosis, dyspepsia, a feeling of tension in the mammary glands, weight gain, stimulation of growth hormone-dependent neoplasms, skin pigmentation in the form of spots.

Interaction

Regular intake of certain drugs (drug) (barbiturates, phenylbutazone, hydantoin, rifampicin, ampicillin, etc.) may lead to a decrease in effectiveness. There may be a change in the need for oral hypoglycemic drugs.

Routes of administration

Inside.

Precautions for Estradiol valerate

Before the beginning of treatment it is necessary to undergo general and gynecological examination, including examination of the mammary glands.

The drug should be discontinued immediately in the following cases: first migraine-like occurrence or frequent occurrence of an unusually severe headache, impaired perception (visual or hearing impairment), first signs of thrombophlebitis or thromboembolic events (unusual foot pains or swelling of the legs, stitching pains during breathing or coughing unclear etiology), difficulty breathing and a feeling of pain in the chest cavity, planned operations (6 weeks before the operation), immobilization (for example after accidents), is caused jaundice, hepatitis, the appearance of itching throughout the body, the increase in epileptic seizures, a strong increase in blood pressure (arterial pressure).

If uterine bleeding occurs, it is necessary to consult a doctor to find out their cause.